Effect of aminated gelatin on the nasal absorption of insulin in rats

Biological and Pharmaceutical Bulletin

Volumn 28, Issue 3, 2005, Pages 510-514

  Seki, Toshinobu ^a   Kanbayashi, Hiroshi ^a   Nagao, Tomonobu ^a   Chono, Sumio ^a   Tomita, Mikio ^b   Hayashi, Masahiro ^b   Tabata, Yasuhiko ^c   Morimoto, Kazuhiro ^a  

^a HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Absorption enhancer; Aminated gelatin; Insulin; Nasal absorption

Indexed keywords

CARBOXYFLUORESCEIN; DRUG ABSORPTION ENHANCER; DRUG CARRIER; ETHYLENEDIAMINE; GELATIN; GLUCOSE; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG;

AMINATION; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GLUCOSE BLOOD LEVEL; INSULIN TREATMENT; MALE; MOLECULAR WEIGHT; NONHUMAN; NOSE MUCOSA; RAT; SYNTHESIS;

ADMINISTRATION, INTRANASAL; AMINATION; ANIMALS; GELATIN; INSULIN; MALE; NASAL MUCOSA; RATS; RATS, WISTAR;

EID: 21144448919     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.28.510     Document Type: Article

References (20)

1. Davis S. S., Ilium L., Clin. Pharmacokinet., 42, 1107-11 28 (2003).
2. Verhoef J. C., Merkus F. W. H. M., "Drug Absorption Enhancement: Concepts, Possibility, Limitations and Trends," ed. by deBoer A. G., Harwood Academic Publishers, Singapore, 1994, pp. 119-153.
3. Morimoto K., Miyazaki M., Kakemi M., Int. J. Pharm., 113, 1-8 (1996).
4. Dondeti P., Zia H., Needham T. E., Int. J. Pharm., 127, 115-133 (1995).
5. Marttin E., Verhoef J. C., Romeijin S. G., Merkus F. W. H. M., Pharm. Res., 12, 1151-1157 (1995).
6. Merkus F. W. H. M., Schiepper N. G. M., Hermens W. A. J. J., Romeijin V. S. G., Verhoef J. C., J. Control. Release, 24, 201-208 (1993).
7. Illum L., Farraj N. F., Davis S. S., Pharm. Res., 11, 1186-1189 (1994).
8. Aspden T. J., Illum L., Skaugrud Ø., Eur. J. Pharm. Sci., 4, 23-31 (1996).
9. Natsume H., Iwata S., Ohtake K., Miyamoto M., Yamaguchi M., Hosoya K., Kobayashi D., Sugibayashi K., Morimoto Y., Int. J. Pharm., 185, 1-12 (1999).
10. Miyamoto M., Natsume H., Iwata S., Ohtake K., Yamaguchi M., Kobayashi D., Sugibayashi K., Yamashita M., Morimoto Y., Eur. J. Pharm. Biopharm., 52, 21-30 (2001).
11. Wang J., Sakai S., Deguchi Y., Bi D., Tabata Y., Morimoto K., J. Pharm. Pharmacol., 54, 181-188 (2002).
12. Hirai S., Yashiki T., Matsuzawa H., Int. J. Pharm., 7, 317-325 (1981).
13. Hirai S., Yashiki T., Matsuzawa H., Int. J. Pharm., 9, 165-172 (1981).
14. Schipper N. G. M., Varum K. M., Artursson P., Pharm. Res., 13, 1686-1692 (1996).
15. Schipper N. G. M., Olson S., Hoogstraate J. A., deBoer A. G., Varum K. M., Artursson P., Pharm. Res., 14, 923-929 (1997).
16. Hirai S., Ikenaga T., Matsuzawa T., Diabetes, 27, 296-299 (1978).
17. McEwan G. T. A., Jepson M. A., Hirst B. H., Simmons N. L., Biochim. Biophys. Acta, 1148, 51-60 (1993).
18. Ohtake K., Maeno T., Ueda H., Natsume H., Morimoto Y., Pharm. Res., 20, 153-160 (2003).
19. Wang J., Tauchi Y., Deguchi Y., Morimoto K., Tabata Y., Ikada Y., Drug Delivery, 7, 237-243 (2000).
20. Fernandez-Urrusuno R., Calvo P., Remunan-Lopez C., Vila-Jato J. L., Alonso M. J., Pharm. Res., 16, 1576-1581 (1999).